As of 2025, ICIs such as pembrolizumab (anti-PD-1) and nivolumab, with or without ipilimumab (anti-CTLA-4), are integrated into clinical practice in both neoadjuvant and first-line settings for MSI-H/dMMR CRC. This evidence concerns the gene CTLA4 and colorectal carcinoma.